Effect of Charcoal on Gastrointestinal Absorption of Tiotropium

• Status: Completed
• Trial end date: 2019-06-19
• Target enrollment: 0
• Participant gender: All

Summary

The study will assess how efficiently activated charcoal will block absorption of tiotropium via the gastro intestinal track. Pharmacokinetics of tiotropium will be compared after orally administered tiotropium capsule with and without concomitant activated charcoal administration in healthy volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Orion Corporation, Orion Pharma
• Treatments: Charcoal; Tiotropium Bromide

Criteria

Inclusion Criteria:

1. Written informed consent (IC) obtained.

2. Healthy males and females, aged 18-60

3. Normal weight at least 50 kg.

Exclusion Criteria:

1. Evidence of a clinically significant cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological or psychiatric disease.

2. Any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study.

3. Any clinically significant abnormal laboratory value or physical finding that may interfere the interpretation of study result or constitute a health risk for the subject if he/she participates in the study.

4. Known hypersensitivity to tiotropium bromide, atropine or its derivatives or to the excipients of the drug.

5. Pregnant or lactating females.

6. Females of childbearing potential not using proper contraception.